In vitro experiments have shown the exertion of anti-NASH effects by maintaining mitochondrial homeostasis and inhibiting NLRP3 inflammasome activation (Wang et al., 2021). Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.